Arcede Pharma räknar med att slutföra den sista toxikologistudien i augusti 2023 och har aviserat om...
Maven Wireless publicerade den 15 augusti 2023 bolagets delårsrapport för det andra kvartalet 2023 o...
Fortsatt leverans från bolaget Omsättningen i kvartalet uppgick till 30,2 mkr, vilket motsvarar en t...
Redeye comments on Better Collective’s acquisition of Swedish sports media brands that will expand t...
Redeye comments on Physitracks’s Q2-results, wherein the reported figures generally align with our e...
EBITA -50% vs. ABGSCe, in-line with PW Solid FCF driven by positive WC development Conference call a...
Redeye retains its positive view of Hexatronic following a solid Q2 2023 but with soft guidance for ...
Agilyx released a positive update to their 10 tonne-per-day facility progress with Toyo Styrene this...
En optimerad försäljningsmix resulterade i en rekordhög nettovinst för kvartalet och vi prognostiser...
Redeye updates its estimates and valuation following Remedy’s H1 report, where we increase our cost ...
Q2: EBITDA PLN 69m vs. ABGSCe of PLN 112m Paper market balance under pressure from weak demand Fair ...
Tough comps coming up, Q2e helped by performance fees EPS cut by 7% for '23e driven by lower corpora...
Redeye reiterates its fair value range following a solid Q2’23 report that presented surprisingly so...
Richard Carter will take the helm, joining on 18 SepExtensive experience, e.
As a part of its cost-saving program, DT today initiated change negotiations which may end up in a t...
8% margin-driven adj. EBITA missExpect some more margin headwinds on weak SEKCompany cautious near-t...
Carlsquare Equity Research sammanfattar sina första intryck av Spotlight Groups kv2-rapport.
Redeye comments on FlexQube’s decision to carry out a fully guaranteed rights issue of SEK75m and th...
Redeye comments on the inclusion of the last patient in the Lenvima arm of the phase IIa trial of fo...
H&D Wireless intäkter i kv2 2023 blev ca 6 procent lägre än vår prognos.
